Although targeted therapies against some of the major EMT-inducers have been vastly used to treat cancer patients (e.g., anti-EGFR tyrosine kinase inhibitors), others have repeatedly failed in clinical trials (e.g., anti-TGF-β inhibitors) [15,145]. Here, TGFB1 is linked to cancer.